Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 107 | 0.82 |
| pathways Reactome | 1 pathway; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 11821
Sealed predictions
- UBIAD1 in dopamine neurons, braak+0.08 (p 0.842) → -0.66 (p 0.053)receipt 11829
Swarm cases
receipt 11829: UBIAD1 in dopamine neurons, braak
- power
- full sample -0.34 (p 0.167, n 18), 95% CI -0.70 to +0.15. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.173, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.26, sign flips 0; without severely affected donors -0.34 (p 0.167, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.72 (p 7.0e-4, n 18) vs -0.34 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for UBIAD1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up UBIAD1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.68 p 0.016 (needs p < 1.9e-4)
Receipts
loading the receipts